About ASND

Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs.The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed Phase 2 studies in adults and children with growth hormone deficiency, or GHD. Ascendis Pharma expects to initiate a Phase 3 pediatric study of TransCon Growth Hormone in mid-2016. Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension, or PAH. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ASND is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 212.2 M 2.1215E+08 234 234 0.31% 0.00305951 1.4 M 1423670
UBIO Proshares UltraPro Nasdaq Biotechnology 28.4 M 2.839E+07 227 227 0.2% 0.00196358 182 K 181940
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 33.4 M 3.34E+07 82 82 0.08% 0.00079 26 K 26430
ADRU Invesco BLDRS Europe Select ADR Index Fund 11.6 M 1.16E+07 69 69 0.1% 0.00096 11 K 11154
IBB iShares Nasdaq Biotechnology Index Fund 7.3 B 7.33983E+09 221 221 0.74% 0.0074 54.6 M 5.46461E+07
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.1 B 2.1E+09 1,002 1002 0.04% 0.000427533 899 K 898637